~~<i id='F01021AB52'><strike id='F01021AB52'><tt id='F01021AB52'><pre id='F01021AB52'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：hotspot 2025-09-29 23:12:34 - browse：3

An FDA sign — health policy coverage from STAT — Sarah Silbiger/Getty Images

WASHINGTON — There’s about to be a new acronym in town.

The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

That overhaul includes a new name: Meet the Office of Inspections and Investigations.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Medicaid rebukes states for mistakenly disenrolling children

explore

hotspot

focus

hotspot

Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The (many) problems with a new study criticizing cancer screening

What drug price negotiations mean for Medicare Part D

Humana sues Biden admin over Medicare Advantage audit rule

Advances in CAR

How to save health care price transparency rules

leisure time

entertainment

explore

After affirmative action ruling, medical educators look to 'holistic review'

A new House health package & hospitals’ new site

In age of alternative facts, a scholarly course on calling out crap

NIH nominee Bertagnolli will get October confirmation hearing

Alkermes shareholders re

Readout Newsletter: CAR

United colonoscopy coverage change 'may cost lives,' doctors say

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Psychedelics group wrestles with new pharma identity

What drug price negotiations mean for Medicare Part D

hotspot

Male and female sex labels in research insufficient, scientists say

Crinetics acromegaly drug succeeds in late

Male and female sex labels in research insufficient, scientists say

'Make People Better': The CRISPR babies story you probably don't know

AstraZeneca chief proposes a novel edit to the drug pricing bill

Ethical issues complicate the benefits of medical crowdfunding

hotspot

hotspot

focus

hotspot